Clinical Trial Update: A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing once-weekly somapacitan with daily Norditropin in adults with growth hormone deficiency; completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency in Adults

Drugs mentioned

• Norditropin FlexPro (somatropin)
• Somapacitan (NNC0195-0092) (somapacitan)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2020-10-06